Advent International buys more than 50 per cent stake for Rs 6300 crore in this pharma company. Do you own it?
Advent International buys more than 50 per cent stake for Rs 6300 crore in this pharma company. Do you own it?

Advent International buys more than 50 per cent stake for Rs 6300 crore in this pharma company. Do you own it?

Advent is expected to buy 51 per cent of the promoter’s stake in the company and launch an open offer for an additional 26 per cent

Bhavya Rathod Article rating: 4.3

The company released a press release on Monday, stating Advent International has entered into definitive agreement to acquire significant stake in the company and intends to explore the merger of  its portfolio company

Only buyers: Shares of this pharmaceutical company are locked at 20 per cent upper circuit. Do you own it?
Only buyers: Shares of this pharmaceutical company are locked at 20 per cent upper circuit. Do you own it?

Only buyers: Shares of this pharmaceutical company are locked at 20 per cent upper circuit. Do you own it?

This stock is currently available at a PE multiple of 21.47 and an ROE of 9.68, all of which indicate good management effectiveness.

Kiran Shroff Article rating: 4.3

This stock is currently available at a PE multiple of 21.47 and an ROE of 9.68, all of which indicate good management effectiveness.

This pharma company stock went 8 per cent high, do you own it?
This pharma company stock went 8 per cent high, do you own it?

This pharma company stock went 8 per cent high, do you own it?

With its shares up 8 per cent, the Indian multinational pharmaceutical company posted a net profit of Rs 130 crore in the second quarter, while its turnover increased to Rs 4,145 crore.

Kiran Shroff Article rating: 5.0

This pharma company stock went 8 per cent high, do you own it?                                                                                                                                                                                                       With its shares up 8 per cent, the Indian multinational pharmaceutical company posted a net profit of Rs 130 crore in the second quarter, while its turnover increased to Rs 4,145 crore.

Pharma stocks outperform; Dr Reddys Laboratories emerges as top BSE Sensex gainer
Pharma stocks outperform; Dr Reddys Laboratories emerges as top BSE Sensex gainer

Pharma stocks outperform; Dr Reddys Laboratories emerges as top BSE Sensex gainer

On the sectoral front, indices traded with modest gains with the pharma sector outperforming

Shreya Chaware Article rating: 5.0

In the first hour of the trading session, Sensex and Nifty were able to recover some of the opening losses and traded flat. At the time of market opening, 27 out of 30 stocks on Sensex were trading in the red. The top gainers on Sensex are Dr Reddy’s Laboratories, Reliance Industries, and Maruti Suzuki whereas the top losers include Asian Paints, Tata Steel, Power Grid Corporation, L&T, and UltraTech Cement.  

DSIJ MINDSHARE

Mkt Commentary4-Nov, 2024

Multibaggers4-Nov, 2024

Penny Stocks4-Nov, 2024

Mindshare4-Nov, 2024

Mindshare4-Nov, 2024

Knowledge

MF28-Oct, 2024

Personal Finance28-Oct, 2024

Technical23-Oct, 2024

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR